These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 115634)

  • 1. Dopamine agonist potencies of ergolines.
    Lew JY; Nakamura S; Battista AF; Goldstein M
    Commun Psychopharmacol; 1979; 3(3):179-83. PubMed ID: 115634
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of (3H)-terguride and (3H)-spiperone binding to dopamine receptors in the rat striatum.
    Valchár M; Dobrovský K; Krejcí I; Dlabac A
    Act Nerv Super (Praha); 1989 Apr; 31(1):77-9. PubMed ID: 2675526
    [No Abstract]   [Full Text] [Related]  

  • 3. One-trial conditioned rotation in rats.
    Silverman PB
    NIDA Res Monogr; 1989; 95():540-1. PubMed ID: 2577050
    [No Abstract]   [Full Text] [Related]  

  • 4. Dopaminephilic properties of ergot alkaloids.
    Goldstein M; Lew JY; Nakamura S; Battista AF; Lieberman A; Fuxe K
    Fed Proc; 1978 Jun; 37(8):2202-6. PubMed ID: 26607
    [No Abstract]   [Full Text] [Related]  

  • 5. Interaction of pergolide with central dopaminergic receptors.
    Goldstein M; Lieberman A; Lew JY; Asano T; Rosenfeld MR; Makman MH
    Proc Natl Acad Sci U S A; 1980 Jun; 77(6):3725-8. PubMed ID: 6932044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of lergotrile or apomorphine induced turning behavior by haloperidol and clozapine.
    Nakamura S; Engel J; Goldstein M
    Commun Psychopharmacol; 1978; 2(3):185-90. PubMed ID: 29742
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine antagonist binding increases in two behaviorally distinct striatal denervation syndromes.
    Thal L; Mishra RK; Gardner EL; Horowitz SG; Varmuza S; Makman MH
    Brain Res; 1979 Jul; 170(2):381-6. PubMed ID: 572733
    [No Abstract]   [Full Text] [Related]  

  • 8. [Dopamine agonists in the therapy of parkinson syndrome].
    Kapfhammer HP; Rüther E
    Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
    [No Abstract]   [Full Text] [Related]  

  • 9. Dopamine control of seizure propagation: intranigral dopamine D1 agonist SKF-38393 enhances susceptibility to seizures.
    Turski WA; Cavalheiro EA; Ikonomidou C; Bortolotto ZA; Klockgether T; Turski L
    Synapse; 1990; 5(2):113-9. PubMed ID: 2137942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Localization of dopamine receptors in rat brain.
    Reisine TD; Nagy JI; Fibiger HC; Yamamura HI
    Brain Res; 1979 Jun; 169(1):209-14. PubMed ID: 455093
    [No Abstract]   [Full Text] [Related]  

  • 11. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa.
    Brannan T; Knott P; Kaufmann H; Yahr M
    Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of GYKI-32 887 on dopamine (D2) and serotonin (5-HT1 and 5-HT2) receptors.
    Berzétei IP; Bagdy E; Hardy M; Borsy J
    Pol J Pharmacol Pharm; 1985; 37(3):237-42. PubMed ID: 4070077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissociable properties of dopamine neurons im the nigrostriatal and mesolimbic dopamine systems.
    Koob GF; Del Fiacco M; Iversen SD
    Adv Biochem Psychopharmacol; 1977; 16():589-95. PubMed ID: 560793
    [No Abstract]   [Full Text] [Related]  

  • 14. Interactions of exogenous L-dopa with nigrostriatal dopaminergic neurons in Parkinson's disease.
    Melamed E
    Adv Neurol; 1990; 53():61-6. PubMed ID: 2173376
    [No Abstract]   [Full Text] [Related]  

  • 15. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation.
    Hu XT; White FJ
    Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions of a partial ergoline with dopamine receptors in vivo and in vitro.
    Fuxe K; Goldstein M; Agnati LF; Köhler C; Lew JY; Okada K
    Acta Physiol Scand; 1983 Feb; 117(2):303-5. PubMed ID: 6869037
    [No Abstract]   [Full Text] [Related]  

  • 17. Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
    Knoll J
    Adv Neurol; 1990; 53():425-9. PubMed ID: 2122648
    [No Abstract]   [Full Text] [Related]  

  • 18. Indirect evidence for a feedback loop mechanism between two central dopaminergic pathways: preliminary results.
    Yehuda S
    Commun Psychopharmacol; 1979; 3(2):115-9. PubMed ID: 467002
    [No Abstract]   [Full Text] [Related]  

  • 19. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
    Koller WC
    J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic levodopa or pergolide administration induces down-regulation of dopamine receptors in denervated striatum.
    Reches A; Wagner HR; Jackson-Lewis V; Yablonskaya-Alter E; Fahn S
    Neurology; 1984 Sep; 34(9):1208-12. PubMed ID: 6540406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.